Seeking Alpha

Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's...

Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.
Comments (4)
  • A material fact would be what percentage of QCOR's revenues and profits are represented by Acthar overall, and of that amount, what percentage has come from Aetna reimbursements..

     

    Eiso
    19 Sep 2012, 01:07 PM Reply Like
  • 100% of profits and 5% from Aetna from what i can find.
    19 Sep 2012, 04:17 PM Reply Like
  • This is straight from the Questcor (QCOR) Press Release:

     

    "Currently, the Company does not believe that the bulletin represents a material change in insurance coverage for Acthar by Aetna. During 2012, Aetna has accounted for approximately 5% of the Company's shipped prescriptions for Acthar. Based on its current assessment of the Clinical Policy Bulletin, the Company does not believe that the bulletin will have a material impact on the Company's results of operations."
    19 Sep 2012, 04:45 PM Reply Like
  • I am buying tomorrow
    20 Sep 2012, 02:51 AM Reply Like
DJIA (DIA) S&P 500 (SPY)